JP2010525023A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525023A5
JP2010525023A5 JP2010504682A JP2010504682A JP2010525023A5 JP 2010525023 A5 JP2010525023 A5 JP 2010525023A5 JP 2010504682 A JP2010504682 A JP 2010504682A JP 2010504682 A JP2010504682 A JP 2010504682A JP 2010525023 A5 JP2010525023 A5 JP 2010525023A5
Authority
JP
Japan
Prior art keywords
alkyl
methyl
hydrogen
hydroxy
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525023A (ja
JP5379787B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/054977 external-priority patent/WO2008129071A1/en
Publication of JP2010525023A publication Critical patent/JP2010525023A/ja
Publication of JP2010525023A5 publication Critical patent/JP2010525023A5/ja
Application granted granted Critical
Publication of JP5379787B2 publication Critical patent/JP5379787B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504682A 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤 Expired - Fee Related JP5379787B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2007/003603 2007-04-24
EP2007003603 2007-04-24
PCT/EP2008/054977 WO2008129071A1 (en) 2007-04-24 2008-04-24 Inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2010525023A JP2010525023A (ja) 2010-07-22
JP2010525023A5 true JP2010525023A5 (enExample) 2011-06-16
JP5379787B2 JP5379787B2 (ja) 2013-12-25

Family

ID=39529321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504682A Expired - Fee Related JP5379787B2 (ja) 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤

Country Status (3)

Country Link
US (2) US8841315B2 (enExample)
JP (1) JP5379787B2 (enExample)
WO (1) WO2008129071A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9093366B2 (en) 2012-04-09 2015-07-28 Transphorm Inc. N-polar III-nitride transistors

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011231975B2 (en) * 2010-03-22 2014-07-03 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
CA2848615C (en) 2011-09-16 2020-02-25 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
US9108926B2 (en) 2011-09-16 2015-08-18 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
US8598937B2 (en) 2011-10-07 2013-12-03 Transphorm Inc. High power semiconductor electronic components with increased reliability
US8803246B2 (en) 2012-07-16 2014-08-12 Transphorm Inc. Semiconductor electronic components with integrated current limiters
CN105283453B (zh) * 2012-10-18 2018-06-22 拜耳药业股份公司 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物
ES2597232T3 (es) 2012-10-18 2017-01-17 Bayer Pharma Aktiengesellschaft 4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona
JP6277195B2 (ja) 2012-10-18 2018-02-07 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含んでいる5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体
PL2928878T3 (pl) 2012-11-15 2017-04-28 Bayer Pharma Aktiengesellschaft Pochodne 5-fluoro-N -(pirydyn-2-ylo)pirydyno-2-aminy zawierające grupę sulfoksyiminową
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
US9087718B2 (en) 2013-03-13 2015-07-21 Transphorm Inc. Enhancement-mode III-nitride devices
US9245993B2 (en) 2013-03-15 2016-01-26 Transphorm Inc. Carbon doping semiconductor devices
US9770445B2 (en) 2013-07-04 2017-09-26 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors
US9443938B2 (en) 2013-07-19 2016-09-13 Transphorm Inc. III-nitride transistor including a p-type depleting layer
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
CA2944251C (en) 2014-04-01 2022-10-18 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
CA2945237C (en) 2014-04-11 2022-09-06 Ulrich Lucking Novel macrocyclic compounds
US9543940B2 (en) 2014-07-03 2017-01-10 Transphorm Inc. Switching circuits having ferrite beads
US9318593B2 (en) 2014-07-21 2016-04-19 Transphorm Inc. Forming enhancement mode III-nitride devices
CA2964683A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
EP3207038B1 (en) 2014-10-16 2018-08-22 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
JP2018509439A (ja) 2015-03-24 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト 多発性骨髄腫を治療するための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用
US20180050040A1 (en) 2015-03-24 2018-02-22 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n--1,3,5-triazin-2-amine for treating lymphomas
EP3539961B1 (en) 2015-06-29 2021-10-06 Astrazeneca AB Polycyclic amide derivatives as cdk9 inhibitors
US10717749B2 (en) 2015-09-29 2020-07-21 Bayer Pharma Aktiengesellschaft Macrocyclic sulfondiimine compounds
CN108368129B (zh) 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CN108604597B (zh) 2016-01-15 2021-09-17 创世舫电子有限公司 具有al(1-x)sixo栅极绝缘体的增强模式iii-氮化物器件
US10224401B2 (en) 2016-05-31 2019-03-05 Transphorm Inc. III-nitride devices including a graded depleting layer
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
SG11202006470RA (en) 2018-02-13 2020-08-28 Bayer Ag Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2401748A1 (en) * 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9093366B2 (en) 2012-04-09 2015-07-28 Transphorm Inc. N-polar III-nitride transistors

Similar Documents

Publication Publication Date Title
JP2010525023A5 (enExample)
JP2011502956A5 (enExample)
JP2017502940A5 (enExample)
JP2010525025A5 (enExample)
RU2012143897A (ru) Замещенные пиримидины как антагонисты рецепторов простагландина d2
JP2016520131A5 (enExample)
JP2015535277A5 (enExample)
JP2011137006A5 (enExample)
JP2013509431A5 (enExample)
JP2013528204A5 (enExample)
JP2013510125A5 (enExample)
JP2009533410A5 (enExample)
JP2016506958A5 (enExample)
JP2015517579A5 (enExample)
JP2004536814A5 (enExample)
JP2013510124A5 (enExample)
JP2016532673A5 (enExample)
JP2011519854A5 (enExample)
JP2010540509A5 (enExample)
JP2016500661A5 (enExample)
JP2020506951A5 (enExample)
JP2013544860A5 (enExample)
JP2016505021A5 (enExample)
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета